Gerald E. Quirk - 19 Nov 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Reporting relationship: Chief Legal & Compliance Offic
Issuer ticker: SYRS
Reported as of: 19 Nov 2024
Net transaction value: -$10,321
SEC form: 4
Accepted by SEC: 20 Nov 2024, 17:00:12 UTC
Prior SEC filing: 02 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Todd Rosenthal, as attorney-in-fact

Key filing fact

Gerald E. Quirk filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 20 Nov 2024.

Key facts

This page summarizes Gerald E. Quirk's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Nov 2024, 17:00.

Change

Previous filing in this sequence was filed on 02 Oct 2024.
Current net transaction value: -$10,321.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRS transaction

Common Stock

Sale

Transaction value: $10,321
Shares: -46,657
Change %: -100%
Price: $0.2212
Shares after: 0
Date: 19 Nov 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2211 to $0.2249, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.